Bruker

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions tailored for molecular and materials research, as well as industrial and applied analysis. The company manufactures a range of scientific instruments and diagnostic tests primarily for clients in the life sciences, pharmaceutical, and biotechnology sectors. Bruker operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST), with the BSI CALID segment generating the highest revenue. The company has a significant revenue presence in the Asia Pacific region, reflecting its global reach and commitment to advancing scientific research and innovation. Additionally, Bruker Cellular Analysis focuses on cell biology, facilitating the exploration of cellular phenomes and the mastery of single-cell analysis for laboratories.

Frank Laukien

President and CEO

Rohan Thakur

President

57 past transactions

RECIPE

Acquisition in 2025
RECIPE is a clinical kit manufacturer with a focus on CE-IVD solutions for HPLC and LC-MS/MS kits. Full kits for LC-MS/MS, HPLC, and photometry are among their offerings, along with calibrators, controls, optimization mixes, internal standards, and instruments. MS/MS parameter optimization and the ensuing analytical system verification are the goals of optimization mixtures.

Terrain Bio

Seed Round in 2025
Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhance the expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines.

PrognomiQ

Series D in 2024
PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Dynamic Biosensors

Acquisition in 2024
Dynamic Biosensors GmbH, based in Munich, Germany, specializes in biomolecular interaction analysis solutions. The company offers the switchSENSE platform, which features the switchSENSE Analyzer and switchSENSE Biochip, enabling label-free interaction analysis through electrically actuated switchable DNA interfaces. These products facilitate various applications, including protein-protein, DNA-protein, and DNA-DNA analysis. By utilizing switchSENSE technology, Dynamic Biosensors provides highly sensitive measurement data that helps biotechnology institutions enhance the quality of their research while reducing the time and costs associated with molecular measurements.

NovAliX

Corporate Round in 2024
NovAliX is a research organization specializing in drug discovery and pharmaceutical development. It provides a range of integrated services designed to address the outsourcing needs of the pharmaceutical industry, from initial discovery through to manufacturing. Utilizing proprietary technologies such as surface plasmon resonance (SPR), X-ray protein crystallography, and advanced NMR techniques, NovAliX offers comprehensive support for small molecule drug discovery and biologics characterization. The company's collaborative approach enables clients to access a unique combination of screening, medicinal chemistry, and structural biology, facilitating the development of effective drugs. Additionally, NovAliX conducts thorough analyses of active pharmaceutical ingredients (APIs) and polymorphism studies, supporting pharmaceutical development and manufacturing teams in their efforts to bring new therapies to market.

Tornado Spectral Systems

Acquisition in 2024
Tornado Spectral Systems designs, manufactures, and distributes optical spectroscopy instruments for sample identification, detection, diagnosis, and imaging. The company provides optical platforms for laboratory use, OEM integration, and to upgrade existing equipment; and nanophotonics solutions that offers high-resolution optical coherence tomography measurements across a range of ophthalmic and materials characterization applications. Founded in 2010, Tornado Spectral Systems is a developer of real-time optical process analyzers and imaging solutions using a portfolio of patents that includes Tornado's foundational and revolutionary High Throughput Virtual Slit (HTVS). The HTVS technology allows the best Raman analysis currently achievable anywhere. The superior performance of Tornado’s HyperFlux™ PRO Plus Raman spectroscopy system allows for more accurate chemical identification and quantitation even with challenging mixtures and low concentrations, faster measurements of dynamic reactions, and low laser power operation in hazardous environments. HyperFlux PRO Plus uses a proprietary HTVS-enabled spectrometer to deliver better Raman sensitivity than ever before possible, making it an ideal solution for production line and laboratory settings. Combined with their small size and low cost, Tornado’s non-destructive, real-time measurement solutions offer numerous benefits for established analytical practice and facilitate broader adoption of Raman methods for pharmaceutical, petrochemical, food, biotech, and other applications.

Nion

Acquisition in 2024
Nion is a company that creates scientific scanning transmission electron microscopes and other electron-optical devices. They collaborate closely with customers to design devices that address real-world problems. They combine a clean, bakeable vacuum to reduce contamination, modern electron optics to enable immense resolution and a range of working modes, and flexibility to allow the instruments to be modified for new applications even after they have been installed.

Tome Biosciences

Series A in 2023
Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

MIRO Analytical

Acquisition in 2023
MIRO Analytical manufactures multi-compound gas analyzers to take action on global warming and air pollution. MIRO Analytical was founded in 2018 and was headquartered in Zurich, Switzerland.

PhenomeX

Acquisition in 2023
PhenomeX is a functional cell biology company focused on advancing research by providing tools that enhance the understanding of cellular behavior. The company enables researchers to explore the full potential of each cell, offering live cell biology research solutions that deliver in-depth insights into cellular functions. By facilitating a comprehensive analysis of cell behavior, PhenomeX aims to contribute significantly to the field of functional cell biology and its applications in improving human health.

Mercy BioAnalytics

Series A in 2023
Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection by utilizing a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles (EVs), which are abundant in blood and provide critical information about their parent cells. By leveraging these EVs, Mercy BioAnalytics aims to enable the detection of various types of cancer at its earliest stages, ultimately striving to enhance patient outcomes and save lives.

Biognosys

Acquisition in 2023
Biognosys is a company focused on advancing proteomics, aiming to revolutionize life sciences through the routine analysis of proteomes in research and clinical laboratories globally. The firm provides next-generation proteomics tools that enable precise quantification of large proteomes in biological samples. Utilizing high-resolution mass spectrometry and an innovative parallel signal processing approach, Biognosys delivers exceptional depth and quality of protein expression data. This technology supports more effective discovery and validation of biomarkers and drug targets, equipping researchers across various fields with critical insights into protein analysis. Originating as a spin-off from the renowned proteomics laboratory of Professor Ruedi Aebersold at ETH Zurich, Biognosys is committed to transforming how scientists understand the proteome.

Haystack Oncology

Series A in 2022
Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information.

Navignostics

Seed Round in 2022
Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey. At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancer drug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development. Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners. This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.

Optimal Industrial Automation

Acquisition in 2022
Optimal Industrial Automation is a comprehensive design and build company that specializes in providing software services for various automation systems tailored to diverse clients globally. The company offers a wide range of services, including batch and continuous process automation, electrical services, robotics, product serialization, and training. By functioning as a one-stop shop for automation needs, Optimal Industrial Automation enables clients to streamline their operations and enhance efficiency through its integrated solutions.

PrognomiQ

Venture Round in 2022
PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

PreOmics

Series B in 2022
PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.

Prolab Instruments

Acquisition in 2022
Prolab Instruments is a Swiss technology company specialized in low-flow, high precision liquid chromatography technology and systems.

Molecubes

Acquisition in 2021
MOLECUBES is a spin-off from Ghent University that specializes in the development of modular preclinical imaging systems designed for laboratory environments. Originating from the MEDISIP research group, the company focuses on creating versatile imaging cubes that integrate SPECT, PET, and CT technologies, allowing researchers to conduct high-performance imaging studies on small animals with minimal space requirements. These benchtop platforms are equipped with intuitive wireless acquisition and reconstruction software, making them accessible for users with varying levels of expertise. By prioritizing the needs of end-users, MOLECUBES emphasizes the significance of reliable servicing to enhance the user experience and improve daily imaging practices in preclinical research.

Acuity Spatial Genomics

Acquisition in 2021
Acuity Spatial Genomics specializes in spatial 3D genomic and multiomic analysis, offering a platform that enables simultaneous, genome-wide visualization of the 3D genome in individual cells. Utilizing proprietary technologies such as OligoFISSEQ™ and OligoFISSEQ HD™, the company allows researchers to examine genome organization and 3D chromatin architecture directly in situ. This approach provides a time-efficient and cost-effective means for researchers to gain insights into transcription regulatory programs that influence cell types, states, functions, and disease processes.

Adeptrix

Series A in 2021
cCorp is a developer and manufacturer of analytical reagents and assays that are based on the company’s proprietary platform technology termed Bead Assisted Mass Spectrometry (BAMS). BAMS™ is an innovative and powerful analytical platform that allows immunoassays to be measured by MALDI mass spectrometry for rapid, precise and sensitive target analyte detection. The BAMS platform technology is both multiplexed (capable of measuring multiple target analytes in a single assay) and high-throughput (capable of measuring hundreds to thousands of assays per day), making it amenable for a wide range of bio-analytical applications in drug development, basic research and clinical diagnostics.

Ionpath

Series B in 2020
IonPath, Inc., based in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. Founded in 2014, the company has developed advanced ion beam imaging technology that allows for detailed analysis of tissue biopsies, including fresh, frozen, and formalin-fixed paraffin-embedded (FFPE) samples. This technology goes beyond traditional light microscopy, providing a comprehensive understanding of the tissue microenvironment through highly multiplexed quantitative single-cell analysis. By enabling healthcare providers to obtain actionable insights, IonPath's services facilitate accurate cancer diagnoses and contribute to advancements in human health.

PrognomiQ

Venture Round in 2020
PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Canopy Biosciences

Acquisition in 2020
Canopy Biosciences is a biotechnology company specializing in research tools for gene editing, molecular biology, and personalized medicine. Founded in 2016 and headquartered in St. Louis, Missouri, the company offers a range of products and services designed to enhance scientific discovery in biomedical research. Its gene editing technology, known as TUNR, facilitates targeted modifications in the genome by inserting polyA tracks into specific coding regions, which reduces mRNA levels and subsequently suppresses protein expression. This innovative approach supports researchers at universities, research institutions, and within the biotechnology and pharmaceutical sectors, advancing the fields of genetic engineering and gene expression analysis. Canopy Biosciences operates as a subsidiary of Bruker Corporation.

PMOD Technologies

Acquisition in 2019
PMOD Technologies LLC, founded in 1993 and based in Zurich, Switzerland, specializes in the development of software quantification tools for biomedical imaging in both human and animal research. Initially created at the University Hospital PET Center in Zurich to address the lack of software for positron emission tomography (PET), the PMOD software evolved through collaborations with engineers from Warsaw University of Technology. This led to the establishment of PMOD Technologies LLC in 2003 as a spin-off to further enhance and distribute the software. The company now serves over 550 sites globally, with more than 1,000 active users, and its offerings have expanded to include tools for functional MRI and CT. PMOD Technologies aims to provide researchers with user-friendly and robust software solutions for various tasks, including kinetic modeling, parametric mapping, and image registration, while ensuring exceptional support and services to facilitate their experimental work. Since July 2019, PMOD Technologies has operated as a subsidiary of Bruker Corporation.

Alicona Imaging

Acquisition in 2018
Alicona Imaging is a manufacturer based in Graz, Austria, specializing in optical 3D surface measurement technology. The company focuses on providing advanced metrology systems that measure form and roughness, even in complex and miniaturized geometries. This technology is essential for quality assurance in laboratories and production environments. Alicona Imaging serves various industries, including machine tools, medical technology, forensic science, and microelectronics, enabling clients to enhance product development and optimize processes.

JPK In­stru­ments

Acquisition in 2018
JPK In­stru­ments a lead­ing man­u­fac­tur­er of nano-an­a­lyt­i­cal in­stru­ments - par­tic­u­lar­ly based on atom­ic force mi­cro­scope (AFM) and op­ti­cal tweez­ers sys­tems - for life sci­ences and soft mat­ter ap­pli­ca­tions. Take a clos­er look at our so­lu­tions!

InVivo Biotech Services

Acquisition in 2017
InVivo is a leading contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins. Based in Hennigsdorf, Germany, just outside Berlin, InVivo is an ISO 9001 certified company with over 18 years experience in mammalian cell culture and protein production. As a trusted provider of cost-effective outsourcing solutions, InVivo has worked with a large number of satisfied clients. Companies of all sizes, including small university spin-offs, major research institutes, and biopharmaceutical companies, have taken advantage of our expertise as an independent contract manufacturer.

SCiLS

Acquisition in 2017
SCiLS GmbH, based in Bremen, Germany, specializes in developing software solutions for the analysis and exploration of mass spectrometry data. The company offers innovative tools that include statistical analysis software, advanced visualization viewers, and secure cloud-based services designed for collaborative interpretation of complex mass spectrometry imaging (MSI) data sets. As a subsidiary of Bruker Corporation since 2017, SCiLS focuses on enhancing the capabilities of researchers and scientists in interpreting imaging mass spectrometry data through its tailored software applications.

OncoVision

Acquisition in 2016
Oncovision (GEM Imaging S.A.) is a Spanish technologic start-up company created in 2003 with the initiative of the Corpuscular Physics Institute (CSIC) and the University of Valencia. They work in Molecular Vision applied to Health Sciences focusing in: cancer diagnosis and treatment, and advanced research in neurology, oncology, and cardiology. They are a company focused on Molecular Vision, which creates, develops and markets new medical technologies, global innovations with relevant clinical and economic advantages, often representing a breakthrough in current standards of diagnosis and treatment. ONCOVISION´s original, fresh technology, strong intellectual property, top-level clinical evidence, leading global reference centers, and pioneering protocols, is supported by its dynamic cross-functional team. ONCOVISION is opening unprecedented options in the treatment of cancer and serious cardiac and neurological diseases. Their team and the company’s technologies have been recognized by Spanish and European prestigious institutions. In 2007, the company was selected as one of the “20 Best Technologic Companies in Spain” and won the “National Medical Physics 2007 Congress Award” In 2008, it was one of the “20 Best Health Technology Companies in Europe” by the prestigious European Technology Tour, as well as finalist in the “National 25th Aniversary Enisa Award” Prof. Jose María Benlloch, active member of the company, won in 2008, the well-known “Jaime I” award. Scientists, technicians, and technologists of ONCOVISION have dozens of publications and presentations at scientific and medical conferences worldwide. Their shareholding, based in Valencia, was strengthened in August 2006 by the Spanish venture capital firm Bullnet, unifying its proven track in technological and management capabilities with companies in Spain and Portugal. The company is managed by a multi-task professional team with international experience. With proven clinical and scientific results, differentiated technology with enormous potential for future technological and financial capacity, intellectual property and developing lines, ONCOVISION is today ahead in the Spanish and European Health Industry.

Yingsheng Technology

Acquisition in 2016
Yingsheng Technology Pty Ltd. in Brisbane, Australia, that relate to the 3rd generation Advanced Mineral Identification and Characterization System (AMICS) software package, and respective IP for advanced minerals identification and characterization. AMICS is a highly innovative software platform for automated identification and quantification of mineral and synthetic phases. It can be used in conjunction with either scanning electron microscopes (SEM) and SEM-related energy dispersive X-ray spectrometers (EDS), or now also with novel micro X-ray fluorescence (µXRF) analyzers.

Jordan Valley Semiconductors

Acquisition in 2015
Jordan Valley Semiconductors specializes in providing X-ray metrology solutions tailored for the semiconductor industry, addressing both front-end and back-end applications. Founded in 1982, the company offers a diverse range of products, including advanced metrology tools such as the JVX7200 and VUV700U for ultra-thin film measurements, as well as inspection systems like BedeScan for detecting structural defects in wafers. Their technology utilizes various X-ray techniques, such as reflectometry and diffraction, allowing for precise characterization of thin films used in semiconductor manufacturing. The company's solutions cater to applications including wafer level packaging and the production of compound semiconductors. With headquarters in Austin, Texas, Jordan Valley has manufacturing and research facilities in Migdal Ha'Emek, Israel, and Durham, United Kingdom, along with sales and customer support operations across Asia and Europe.

SkyScan

Acquisition in 2012
SkyScan designs, manufactures, markets and services instruments for 3D X-ray micro-CT imaging for customers in materials and life science. SkyScan is located close to Antwerp, Belgium.

S.I.S. Surface Imaging Systems

Acquisition in 2008
S.I.S. develops, manufactures and distributes advanced atomic force/scanning probe microscopy systems (AFM/SPM) for numerous applications in materials research, including semiconductors, data storage, electronic materials, solar cells, polymers and catalysts. AFM/SPM is a well-established method for ultra-high spatial resolution surface imaging and the characterization of surfaces down to atomic dimensions.

JUWE Laborgeraete

Acquisition in 2008
JUWE Laborgeraete GmbH manufactures analysers and surface area measuring apparatus. The company provides analysers for oxygen, nitrogen, and hydrogen in solids, as well as for carbon and sulphur in ferrous, non-ferrous, and organic materials. It also offers environmental measuring instruments, such as work hygiene, emission measurements, ambient air measurements, and specific surface area determination, as well as systems for water, soil, sludge, and refuse analysis. JUWE Laborgeraete GmbH was founded in 1997 and is based in Viersen, Germany.

Quantron

Acquisition in 2006
Quantron GmbH designs and manufactures optical emission spectrometers for the analysis of metals worldwide. It serves the steel, cast iron, aluminium, solder, and copper industries.

KeyMaster Technologies

Acquisition in 2006
KeyMaster Technologies specializes in the development and manufacture of portable hand-held X-ray fluorescence (XRF) systems designed for a range of applications. The company's offerings include tracer handheld XRF analyzers that utilize Windows CE-based analysis software for spectral analysis, as well as solutions aimed at anti-counterfeiting and brand protection. These systems address security-related challenges by incorporating elemental tagging to secure documents and maintain brand identity. KeyMaster's XRF technology is utilized across various industries, including metals and alloy analysis for metal processing sectors such as automotive, aerospace, and scrap sorting, providing essential tools for positive material identification and quality assurance.

Roentec AG

Acquisition in 2005
Rontec is a manufacturer German of measuring intruments by X-rays. Their specialty are the detectors semiconductors for energy-dispersive x-ray spectroscopy , and in particular the undoped silicon detectors ( silicon sensor diffusion , drift silicon detector ). The doped silicon detectors must be cooled on the one hand to reduce background noise , on the other hand to prevent the migration of dopant; the advantage of undoped detectors is that they need to be much less cooled, especially do not require any liquid nitrogen . They also produce devices implementing these detectors, mostly devices XRF and XRD portable

Princeton Gamma-Tech Instruments

Acquisition in 2005
Princeton Gamma Tech Instruments, Inc. develops and manufactures detection equipment used in the homeland security and industrial markets. The company manufactures gamma-ray and x-ray detectors for the nuclear spectroscopy and research sector. The company is based in Princeton, New Jersey.

Socabim

Acquisition in 2005
Socabim is designs, develops, and markets solutions for X-ray materials research and analytical applications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.